人免疫球蛋白辅助治疗小儿重症肺炎临床分析.docVIP

人免疫球蛋白辅助治疗小儿重症肺炎的临床分析 　　[摘要] 目的 探讨人免疫球蛋白辅助治疗小儿重症肺炎的临床效果。方法 该文研究整群选取研究对象118例，均为2012年4月―2015年6月该院收治的重症肺炎患儿，根据患儿在治疗期间接受的不同治疗措施将所有患儿分为两组，一组患儿为对照组，采用常规治疗联合丹参酮磺酸钠治疗，另一组患儿为观察组，在对照组治疗基础上加用人免疫球蛋白辅助治疗，分析两组治疗方案的有效性。结果 观察组重症肺炎患儿体温恢复正常天数（3.13±1.43）d、炎症消失天数（8.41±1.23）d、咳嗽消失天数（4.32±1.33）d、??音消失天数（6.44±1.65）d及住院天数（10.48±1.54）d明显优于对照组患儿，两组数据对比差异有统计学意义（P0.05）。结论 人免疫球蛋白辅助治疗小儿重症肺炎具有显著的临床效果，可有效缩短患儿症状缓解时间及住院时间，值得推广及采纳。 　　[关键词] 人免疫球蛋白；小儿重症肺炎；效果 　　[中图分类号] R725 [文献标识码] A [文章编号] 1674-0742（2016）05（b）-0069-03 　　[Abstract] Objective To discuss the clinical effect of adjunctive treatment of human immune globulin for severe pneumonia in children. Methods 118 cases of children with severe pneumonia admitted and treated in our hospital from April 2012 to June 2015 were selected as the research objects and divided into two groups according to the different treatment measures during the treatment period， the control group were treated with conventional method combined with salvianolic sodium， the observation group adopted adjunctive treatment of human immune globulin on the basis of the control group， and the effectiveness of the two treatment plans was analyzed. Results The days of body temperature normalization， disappearance time of inflammation， cough and rale and length of stay in the observation group were respectively （3.13±1.43） d， （8.41±1.23） d， （4.32±1.33） d， （6.44±1.65） d and （10.48±1.54） d， which were obviously better than those in the control group， and the differences in data between the two groups were obvious by comparison， P0.05. Conclusion Adjunctive treatment of human immune globulin for severe pneumonia in children has an obvious clinical effect and it can effectively shorten symptom relief time and length of stay of children， which is worth promotion and adopting. 　　[Key words] Human immune globulin； Severe pneumonia in children； Effect 　　重症肺炎是儿科中最常见的一种呼吸道疾病，多发于春、冬季节。主要临床表现为呼吸困难、咳嗽、气促及肺部有??音等，若未及时采取有效的措施进行治疗，易反复发作、引起较多并发症等，严重影响患儿的生长发育。目前临床上逐渐引入人免疫球蛋白进行治疗，均取得了显著的临床效果[1]。为此，